Dutasteride(新髮靈)用於不同嚴重程度的受試者，皆有一定程度之療效。
以Finasteride (柔沛)1 mg治療6個月後未達到顯著臨床效果的雄性禿病 人， 改以Dutasteride(新髮靈) 0.5 mg治療後，有77.4%達到程度不等之改善，於頭髮密度與粗度，平均改善了10.3%及19.8%。年輕的雄性禿病人經過24週治療後，使用dutasteride(新髮靈) 0.5 mg者單位面積髮量平均增加13根，使用Finasteride(柔沛) 1 mg者反而減少4根。
日本的研究以Dutasteride(新髮靈) 0.5 mg治療雄性禿病人，超過9成完成持續52週的治療，且頭頂和前額區域皆明顯改善，僅<1%受試者髮量減少。
參考文獻
1. Lee WS, Lee HJ, Choi GS, et al.: Guidel ines for management of androgenetic alopecia based on BASP
classification–the Asian consensus committee guideline. JEur Acad Dermatol Venereol 2013; 27:1026-1034.
2. Eun HC, Kwon OS, Yeon JH, et al.: Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol 2010; 63:252-258.
3. Tsunemi Y, Irisawa R, Yoshiie H, et al.: Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia. J Dermatol 2016; 43:1051- 1058.
4. Marks LS: 5α-reductase: History and clinical importance. Rev Urol 2004; 6(suppl 9):S11-S21.
5. Blumeyer A, Tosti A, Messenger A, et al.: Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011; Suppl 6:S1-S57.
6. Gupta M, Mysore V: Classifications of patterned hair loss: a review. J Cutan Aesthet Surg 2016; 9: 3-12.
7. Olsen EA, Dunlap FE, Funicella T, et al.: A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47:377-85.
8. Lucky AW, Piacquadio DJ, Ditre CM, et al.: A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004; 50:541-53.
9. Hillmann K, Garcia Bartels N, Kottner J, et al.: A singlecentre, randomized, double-blind, placebo-controlled clinical trial to investigate the efficacy and safety of minoxidil topical foam in frontotemporal and vertex androgenetic alopecia in men. Skin Pharmacol Physiol 2015; 28:236- 244.
10. 蔡長祐、蔡仁雨：台灣男性雄性禿之診療現況，台灣醫界，2008;51:326-330。
11. Messenger AG, Rundegren J: Minoxidil: mechanisms of action on hair growth. Br J Dermatol 2004; 150:186-194.
12. Lulic Z, Inui S, Sim WY, et al.: Understanding patient and physician perceptions of male androgenetic alopecia treatments in Asia-Pacific and Latin America. J Dermatol 2017 Mar 31. doi: 10.1111/1346-8138.13832. [Epub ahead of print]
13. Roberts JL, Fiedler V, Imperato-McGinley J, et al.: Clinical dose ranging studies with finasteride, a type 2 5alphareductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41:555-563.
14. Olsen EA, Whiting DA, Savin R, et al.: Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol 2012; 67:379-386.
15. Kaufman KD, Rotonda J, Shah AK, et al.: Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol 2008; 18:400-406.
16. Rossi A, Cantisani C, Scarnò M, et al.: Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther 2011; 24:455-461.
17. Olsen EA, Hordinsky M, Whiting D, et al.: The importance of dual 5a-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebocontrolled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55:1014-1023.
18. Harcha WG, Martinez JB, Tsai TF, et al.: A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol 2014; 70:489-498.
19. Jung JY, Yeon JH, Choi JW, et al.: Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride. Int J Dermatol 2014; 53:1351-1357.
20. Shanshanwal SJ, Dhurat RS: Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: a randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol 2017; 83:47-54.
